IP Library › Granted Patent US 12,735,390
Granted Patent B2
US 12,735,390 · App. 18/676,067 · Granted Sep 15, 2026

Pyrylium method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators

Inventors: Hazel Joan Hunt (West Sussex, GB); Gary Patrick Reid (Redwood City, CA); Jeffrey Mark Dener (Redwood City, CA); Aaron Dumas (Hoddesdon, GB); Stephen Hyde (Hoddesdon, GB); Conor Marrett-Munro (Hoddesdon, GB); Shaun Stairs (Hoddesdon, GB); Christopher Wise (Hoddesdon, GB)
Assignee: Corcept Therapeutics Incorporated
C07D239/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,735,390
App. No.
18/676,067
Granted
Sep 15, 2026
Kind
B2
Abstract

The present invention provides methods of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators, methods of preparing intermediates of pyrimidine cyclohexyl glucocorticoid receptor modulators, and pyridinium compounds.

Claims (35)

1 . A method of preparing a compound of Formula I:

the method comprising:

(a) forming a first reaction mixture comprising a first solvent, a strong acid, and a compound of Formula VII:

under conditions suitable to prepare the compound of Formula I,

wherein counterion X − is tetrafluoroborate, chloride, bromide, tetrachloroferrate, pentachlorostannate, hexafluorophosphate, butyltriphenylborate, or tetrakis(4-methoxyphenyl)borate.

2 . The method of claim 1 , wherein the first solvent comprises acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, isobutyric acid, isovaleric acid, 4-methylvaleric acid, or 2-ethylcaproic acid.

3 . The method of claim 1 , wherein the strong acid comprises trifluoroacetic acid, trichloroacetic acid, ethane-1,2-disulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, hydrofluoric acid, hydrochloric acid, hydrobromic acid, hypochlorous acid, chloric acid, perchloric acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, trifluoromethanesulfonic acid, camphorsulfonic acid, or combinations thereof.

4 . The method of claim 1 , wherein the strong acid comprises hydrochloric acid.

5 . The method of claim 1 , wherein counterion X − is BF 4 − .

6 . The method of claim 1 , wherein the compound of Formula VII has the structure:

7 . The method of claim 1 , comprising:

(a) forming the first reaction mixture comprising the compound of Formula VII, acetic acid, and concentrated hydrochloric acid, under conditions suitable to prepare the compound of Formula I.

8 . A method of preparing a compound of Formula VII:

comprising

(b) forming a second reaction mixture comprising a pyrylium salt:

a second solvent and a compound of Formula II, or a hydrate thereof:

under conditions suitable to prepare the compound of Formula VII, wherein counterion X − is BF 4 − .

9 . The method of claim 8 , wherein the pyrylium salt is pyrylium tetrafluoroborate having the structure:

10 . The method of claim 8 , wherein the pyrylium salt is present in an amount of from 1 to 3 molar equivalents to the compound of Formula II.

11 . The method of claim 8 , wherein the pyrylium salt is present in an amount of about 1.1 molar equivalents to the compound of Formula II.

12 . The method of claim 8 , wherein the second solvent comprises methanol, ethanol, n-propanol, isopropanol, n-butanol, t-butanol, 1-pentanol, 2-pentanol, 3-pentanol, 2-methyl-1-propanol, 1-methoxy-2-propanol, 4-methyl-2-pentanol, 1-hexanol, 2-hexanol, 1-octanol, or 2-octanol, or combinations thereof.

13 . The method of claim 8 , wherein the second solvent comprises n-propanol or n-butanol.

14 . The method of claim 8 , wherein the compound of Formula II is the monohydrate form:

15 . The method of claim 8 , comprising

(b) forming the second reaction mixture comprising pyrylium tetrafluoroborate in an amount of about 1.1 molar equivalents to the compound of Formula II, n-butanol, and the compound of Formula II, under conditions suitable to prepare the compound of Formula VII.

16 . The method of claim 1 , wherein the compound of Formula VII is prepared by

(b) forming a second reaction mixture comprising a pyrylium salt:

a second solvent and a compound of Formula II, or a hydrate thereof:

under conditions suitable to prepare the compound of Formula VII, wherein counterion X − is BF 4 − .

17 . The method of claim 16 , comprising:

(b) forming the second reaction mixture comprising pyrylium tetrafluoroborate in an amount of about 1.1 molar equivalents to the compound of Formula II, n-butanol, and the compound of Formula II, under conditions suitable to prepare the compound of Formula VII; and

(a) forming the first reaction mixture comprising the compound of Formula VII, acetic acid, and concentrated hydrochloric acid, under conditions suitable to prepare the compound of Formula I.

18 . A compound of Formula VII:

wherein counterion X − is tetrafluoroborate, chloride, bromide, tetrachloroferrate, pentachlorostannate, hexafluorophosphate, butyltriphenylborate, or tetrakis(4-methoxyphenyl)borate.

19 . The compound of claim 18 , wherein the compound of Formula VII has the structure:

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2024
From: HUNT, HAZEL JOAN; REID, GARY PATRICK; DENER, JEFFREY MARK
To: CORCEPT THERAPEUTICS INCORPORATED
Reel/Frame 068060/0891 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2024
From: DUMAS, AARON; HYDE, STEPHEN; MARRETT-MUNRO, CONOR; WISE, CHRISTOPHER; STAIRS, SHAUN
To: PHARMARON UK LTD.
Reel/Frame 068061/0112 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2024
From: PHARMARON UK LTD.
To: CORCEPT THERAPEUTICS INCORPORATED
Reel/Frame 068061/0182 →
Continuity (2)
Provisional Application 63504823 · May 30, 2023
Related Publication 20250011290A1 · Jan 9, 2025
References Cited (76)
US 6852719B2 · Liu et al. · 2005 [cited by applicant]
US 7576076B2 · Clark et al. · 2009 [cited by applicant]
US 7799782B2 · Munson et al. · 2010 [cited by applicant]
US 8173664B2 · Clark et al. · 2012 [cited by applicant]
US 8685973B2 · Clark et al. · 2014 [cited by applicant]
US 8906917B2 · Clark et al. · 2014 [cited by applicant]
US 9321736B2 · Clark et al. · 2016 [cited by applicant]
US 9622979B2 · Bhavarisetti et al. · 2017 [cited by applicant]
US 10238659B2 · Belanoff et al. · 2019 [cited by applicant]
US 10881660B2 · Belanoff et al. · 2021 [cited by applicant]
US 11542238B2 · Hunt et al. · 2023 [cited by applicant]
US 11548856B2 · Hunt et al. · 2023 [cited by applicant]
US 11760731B2 · Hunt et al. · 2023 [cited by applicant]
US 20050245500A1 · Roth et al. · 2005 [cited by applicant]
US 20070155707A1 · Dasse et al. · 2007 [cited by applicant]
US 20100267643A1 · Baron et al. · 2010 [cited by applicant]
US 20130281324A1 · Gouliaev et al. · 2013 [cited by applicant]
US 20210238148A1 · Hunt et al. · 2021 [cited by applicant]
US 20210361651A1 · Chia et al. · 2021 [cited by applicant]
US 20210363112A1 · Hunt et al. · 2021 [cited by applicant]
US 20220220081A1 · Dener et al. · 2022 [cited by applicant]
US 20230183186A1 · Hunt et al. · 2023 [cited by applicant]
US 20230212128A1 · Hunt et al. · 2023 [cited by applicant]
US 20240083856A1 · Hunt et al. · 2024 [cited by applicant]
EP 0037495A1 · 1981 [cited by applicant]
EP 0369627A2 · 1990 [cited by applicant]
EP 0722732A1 · 1996 [cited by applicant]
JP H06128238A · 1994 [cited by applicant]
JP H1017555A · 1998 [cited by applicant]
JP 2000271618A · 2000 [cited by applicant]
WO 0244120A1 · 2002 [cited by applicant]
WO 03084935A2 · 2003 [cited by applicant]
WO 2010052445A1 · 2010 [cited by applicant]
WO 2012129074A1 · 2012 [cited by applicant]
WO 2016061195A1 · 2016 [cited by applicant]
WO 2019236487A1 · 2019 [cited by applicant]
WO 2021226258A1 · 2021 [cited by applicant]
WO 2021226260A1 · 2021 [cited by applicant]
WO 2022140293A1 · 2022 [cited by applicant]
(2023) Eudragit® L 100, https://www.pharmaexcipients.com/product/eudragit-I-100/, 2 pages. [cited by applicant]
International Search Report and Written Opinion issued in related International Patent Application No. PCT/US2019/035229, mailed on Oct. 1, 2019, 10 pages. [cited by applicant]
International Search Report and Written Opinion issued in related International Patent Application. No. PCT/US2005/023675, mailed on Dec. 13, 2005, 11 pages. [cited by applicant]
International Search Report and Written Opinion issued in related International Patent Application. No. PCT/US2012/029376, mailed on Jun. 27, 2012, 8 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Application No. PCT/US2021/030923, mailed on Aug. 18, 2021, 11 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Application No. PCT/US2021/030925, mailed on Aug. 20, 2021, 14 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Application No. PCT/US2021/064428, mailed on Apr. 4, 0222, 16 pages. [cited by applicant]
Ali et al. (Apr. 2, 2004) “Novel N-Arylpyrazolo[3,2-c]-Based Ligands for the Glucocorticoid Receptor: Receptor Binding and in Vivo Activity”, Journal of Medicinal Chemistry, 47(10):2441-2452. [cited by applicant]
Baptista, T. (Jul. 1999) “Body Weight Gain Induced by Antipsychotic Drugs: Mechanisms and Management”, Acta Psychiatr Scand, 100(1):3-16. [cited by applicant]
Bertagna et al. (Jul. 1984) “The New Steroid Analog RU 486 Inhibits Glucocorticoid Action in Man”, The Journal of Clinical Endocrinology and Metabolism, 59(1):25-28. [cited by applicant]
Bhuyan et al. (1998) “Studies on Uracils: Synthesis of Novel Uracil Analogues via 1,5- and 1,6-Intramolecular Cycloaddition Reactions”, XP002355359; Database CA ‘Online’; Chemical Abstracts Service, Columbus, OH, US; Da… [cited by applicant]
Bledsoe et al. (Jul. 12, 2002) “Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Reveals a Novel Mode of Receptor Dimerization and Coactivator Recognition”, Cell, 110(1):93-105. [cited by applicant]
Brophy et al. (Jan. 1983) “Bioavailability of Oral Dexamethasone During High Dose Steroid Therapy in Neurological Patients”, European Journal of Clinical Pharmacology, 24:103-108. [cited by applicant]
Butreddy, Arun (Aug. 2022) “Hydroxypropyl Methylcellulose Acetate Succinate as an Exceptional Polymer for Amorphous Solid Dispersion Formulations: A Review from Bench to Clinic”, European Journal of Pharmaceutics and Bi… [cited by applicant]
Cadepond et al. (1997) “RU486 (mifepristone): Mechanisms of Action and Clinical Uses”, Annual Review of Medicine, 48:129-156. [cited by applicant]
Deshmukh et al. (1998) “Efficient Method for Deamination of Aminopyrimidines”, National Academy Science Letters (India), 21(7-8):247-249. [cited by applicant]
Dorwald, Florencio Z. (2005) “Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design”, Wiley-VCH, 390 pages. [cited by applicant]
Eyles et al. (Jul. 1997) “Oral Delivery and Fate of Poly(Lactic Acid) Microsphere- Encapsulated Interferon in Rats”, Journal of Pharmacy and Pharmacology, 49(7):669-674. [cited by applicant]
Fotherby, K. (Aug. 1996) “Bioavailability of Orally Administered Sex Steroids Used in Oral Contraception and Hormone Replacement Therapy”, Contraception, 54(2):59-69. [cited by applicant]
Fukazawa et al. (1998) “6-Amino-5-Methyluracil Derivativies and Their Use as Thymidine Phosphorylase Inhibitors and Neovascularization Inhibitors”, XP002355358; Database CA ‘Online’; Chemical Abstracts Service, Columbus… [cited by applicant]
Gao et al. (Jun. 1995) “Controlled Release of a Contraceptive Steroid from Biodegradable and Injectable Gel Formulations: In Vitro Evaluation”, Pharmaceutical Research, 12(6):857-863. [cited by applicant]
Groning et al. (May 1996) “Threedimensional Solubility Parameters and Their Use in Characterising the Permeation of Drugs Through the Skin”, Pharmazie, 51(5):337-341. [cited by applicant]
Hidalgo-Aragones et al. (Aug. 1996) “Pharmacokinetics of oestrone-3-O-sulphamate”, The Journal of Steroid Biochemistry and Molecular Biology, 58(5-6):611-617. [cited by applicant]
Hilton et al. (Jul. 1993) “Use of Hydroxypropyl Methylcellulose Acetate Succinate in an Enteric Polymer Matrix to Design Controlled-release Tablets of Amoxicillin Trihydrate”, Journal of Pharmaceutical Sciences, 82(7):7… [cited by applicant]
Hunt et al. (2012) “Discovery of a Novel Non-steroidal GR Antagonist With in Vivo Efficacy in the Olanzapine-induced Weight Gain Model in the Rat”, Bioorganic & Medicinal Chemistry Letters, 22(24):7376-7380. [cited by applicant]
Johnson et al. (Sep. 1995) “Permeation of Steroids through Human Skin”, Journal of Pharmaceutical Sciences, 84(9):1144-1146. [cited by applicant]
Koorneef et al. (2018) “Selective Glucocorticoid Receptor Modulation Prevents and Reverses Nonalcoholic Fatty Liver Disease in Male Mice”, Endocrinology, 159(12):3925-3936. [cited by applicant]
Lee et al. (Apr. 2020) “Reversal of Antipsychotic-induced Weight Gain in Rats with Miricorilant, A Selective Glucocorticoid Receptor (Gr) Modulator”, American Psychiatric Association Annual Meeting, 1 page. [cited by applicant]
Minto et al. (Apr. 1, 1997) “Pharmacokinetics and Pharmacodynamics of Nandrolone Esters in Oil Vehicle: Effects of Ester, Injection Site and Injection Volume”, The Journal of Pharmacology and Experimental Therapeutics, … [cited by applicant]
Nguyen et al. (Sep. 1, 2017) “A Mixed Glucocorticoid/mineralocorticoid Receptor Modulator Dampens Endocrine and Hippocampal Stress Responsivity in Male Rats”, Physiology & Behavior, 178:82-92. [cited by applicant]
Rao, K. Paduranga (1995) “Recent Developments of Collagen-Based Materials for Medical Applications and Drug Delivery Systems”, Journal of Biomaterials Science, Polymer Edition, 7(7):623-645. [cited by applicant]
Rohatagi et al. (1995) “Pharmacokinetic and Pharmacodynamic Evaluation of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled Administration”, Journal of Clinical Pharmacology, 35(12):1187-1193. [cited by applicant]
Rohatagi et al. (Sep. 1, 1995) “Pharmacokinetic Interaction Between Endogenous Cortisol and Exogenous Corticosteroids”, Die Pharmazie, 50(9):610-613. [cited by applicant]
Teutsch et al. (Nov. 1, 1991) “Design of Ligands for the Glucocorticoid and Progestin Receptors”, Biochemical Society Transactions, 19(4):901-908. [cited by applicant]
Tjwa, M.K. (1995) “Budesonide Inhaled Via Turbuhaler: A More Effective Treatment for Asthma than Beclomethasone Dipropionate Via Rotahaler”, Annals of Allergy, Asthma & Immunology, 75(2):107-111. [cited by applicant]
Turner et al. (Oct. 1, 2005) “Structure of the glucocorticoid receptor (NR3C1) gene 5′ untranslated region: identification, and tissue distribution of multiple new human exon 1”, Journal of Molecular Endocrinology, 35(2… [cited by applicant]
Umbricht et al. (Sep. 1994) “Clozapine and Weight Gain”, The Journal of Clinical Psychiatry, 55(Suppl B):157-160. [cited by applicant]